Bristol-Myers Squibb’s Opdivo® (nivolumab) receives FDA approval for treatment of HCC
Bristol-Myers announced the FDA has approved Opdivo (nivolumab) injection for IV use for treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib. Approval has been granted under accelerated approval based on tumor response rate and durability of response. September 22, 2017